CXCL9 and neoplasm: On the other hand, CXCL8 is a target for solid tumor immunotherapy (Dominguez et al., 2017), and CXCL9/10 has been demonstrated to enhance the accumulation of effector T cells at the tumor site and suppress tumor growth (Karin, 2020).